75A50124C00054
Definitive Contract
Overview
Government Description
The overall objective of this contract is to assess the ability of AURAVAX therapeutics? (AURAVAX) novel mucosal adjuvant NANOSTING-002, together with influenza Live Attenuated Virus (LAV) created with codagenix novel synthetic attenuated virus engin
Awardee
Awarding / Funding Agency
Place of Performance
Houston, TX 77009 United States
Pricing
Fixed Price
Set Aside
None
Extent Competed
Full And Open Competition
Est. Average FTE
2
Related Opportunity
22100SOL00003
Auravax Therapeutics was awarded
Definitive Contract 75A50124C00054 (75A501-24-C-00054)
worth up to $749,999
by the HHS Office of the Assistant Secretary for Preparedness and Response
in September 2024.
The contract
has a duration of 2 years 3 months and
was awarded
full & open
with
NAICS 541714 and
PSC AN14
via direct negotiation acquisition procedures with 1 bid received.
Status
(Open)
Last Modified 12/19/25
Period of Performance
9/23/24
Start Date
12/31/26
Current End Date
12/31/26
Potential End Date
Obligations
$750.0K
Total Obligated
$750.0K
Current Award
$750.0K
Potential Award
Award Hierarchy
Definitive Contract
75A50124C00054
Subcontracts
Activity Timeline
Transaction History
Modifications to 75A50124C00054
People
Suggested agency contacts for 75A50124C00054
Competition
Number of Bidders
1
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
PAN3ZK2YLAL2
Awardee CAGE
969E2
Agency Detail
Awarding Office
75A501 BARDA - ASPR / DAAPPO / BARDA DCMA
Funding Office
75A501
Created By
hhsocaleb
Last Modified By
hhsocaleb
Approved By
hhsocaleb
Legislative
Legislative Mandates
None Applicable
Performance District
TX-18
Senators
John Cornyn
Ted Cruz
Ted Cruz
Representative
Sheila Jackson Lee
Modified: 12/19/25